No connection

Search Results

ENOV vs IMTX

ENOV
Enovis Corporation
NEUTRAL
Price
$24.10
Market Cap
$1.39B
Sector
Healthcare
AI Confidence
80%
IMTX
Immatics N.V.
BEARISH
Price
$10.43
Market Cap
$1.4B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ENOV
--
IMTX
--
Forward P/E
ENOV
6.03
IMTX
-5.91
P/B Ratio
ENOV
0.93
IMTX
2.5
P/S Ratio
ENOV
0.62
IMTX
28.98
EV/EBITDA
ENOV
7.38
IMTX
-5.47

Profitability

Gross Margin
ENOV
60.88%
IMTX
-280.87%
Operating Margin
ENOV
6.09%
IMTX
-196.76%
Profit Margin
ENOV
-52.69%
IMTX
0.0%
ROE
ENOV
-58.27%
IMTX
-37.1%
ROA
ENOV
1.09%
IMTX
-18.08%

Growth

Revenue Growth
ENOV
2.6%
IMTX
-64.9%
Earnings Growth
ENOV
--
IMTX
--

Financial Health

Debt/Equity
ENOV
0.92
IMTX
0.03
Current Ratio
ENOV
2.02
IMTX
11.72
Quick Ratio
ENOV
0.8
IMTX
11.07

Dividends

Dividend Yield
ENOV
--
IMTX
--
Payout Ratio
ENOV
0.0%
IMTX
0.0%

AI Verdict

ENOV NEUTRAL

Enovis Corporation presents a classic 'deep value' paradox, characterized by a stable Piotroski F-Score of 4/9 but severe bottom-line profitability issues. While the company trades at a significant discount to book value (P/B 0.93) and a very low forward P/E (6.03), its net profit margin is deeply negative at -52.69%. The stock is supported by a strong track record of earnings beats and bullish analyst targets, but this is countered by a disastrous long-term price trend and high execution risk associated with its acquisition-led growth strategy.

Strengths
Extreme valuation discount with Price/Book at 0.93 and Price/Sales at 0.62
Strong gross margins of 60.88% indicating a healthy core product value
Exceptional earnings track record with consistent beats over 25 quarters
Risks
Severe net losses resulting in a profit margin of -52.69% and negative ROE
High integration risk due to an aggressive acquisition-led growth strategy
Strong bearish technical momentum with a 5-year price decline of 68.9%
IMTX BEARISH

IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.

Strengths
Exceptional short-term liquidity with a Current Ratio of 11.72
Very low leverage with a Debt/Equity ratio of 0.03
Significant analyst price target upside (Target: $18.75 vs Price: $10.43)
Risks
Severe revenue contraction (-64.90% YoY)
Extreme operational inefficiency with Gross Margins at -280.87%
Critical Piotroski F-Score (1/9) signaling fundamental decay

Compare Another Pair

ENOV vs IMTX: Head-to-Head Comparison

This page compares Enovis Corporation (ENOV) and Immatics N.V. (IMTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile